Environmental Allergies ARE an Active Immune Abnormality, and Allergen Immunotherapy is Strongly Indicated
Yes, environmental allergies represent an active, aberrant IgE-mediated immune response to otherwise harmless environmental proteins, and allergen immunotherapy (AIT) is the only disease-modifying treatment that can alter this pathologic immune state. 1
Understanding the Immune Abnormality
Environmental allergies are caused by an IgE-mediated inflammatory response to proteins from inhaled organic particles (pollen, animal dander, mold spores, dust mites) 1. This represents a fundamentally abnormal immune reaction where the body mounts inappropriate type II hypersensitivity responses against harmless environmental antigens 2, 3.
The pathophysiology involves:
- Uncontrolled allergen-activated T cell subsets driving immediate-type hypersensitivity 4
- Excessive Th2-mediated immune responses 5
- Production of allergen-specific IgE antibodies that trigger mast cell degranulation 3
- Chronic inflammatory responses in target organs (nose, eyes, lungs)
This is not a passive condition—it's an active, ongoing immune dysregulation that persists with continued allergen exposure 6.
Why Allergen Immunotherapy is Indicated
Strong Guideline Recommendations
Clinicians should offer or refer patients with allergic rhinitis (with or without asthma) to a clinician who can provide immunotherapy 1. This is a strong recommendation from the 2024 AAO-HNS clinical practice guideline.
AIT is indicated when 2:
- Inadequate symptom control despite pharmacotherapy and avoidance
- Patient desires to reduce morbidity or prevent disease progression
- Undesirable adverse effects from medications
- Avoidance is not possible
Disease-Modifying Mechanism
Unlike medications that only suppress symptoms, AIT actively corrects the underlying immune abnormality through "immunomodulation" 1. The mechanism involves:
- Induction of regulatory T cells (Tregs) that govern pro-allergic effector T cells 4
- Shift from Th2 to Th1/Th0 immune responses, increasing the Th1/Th2 cytokine ratio 6
- Production of blocking IgG4 antibodies (particularly allergen-specific IgG4) 7, 2
- Suppression of IgE production and mediator release from basophils/mast cells 7
- Induction of immune tolerance that persists after treatment discontinuation 1, 8
Recent evidence suggests AIT may also work through trained immunity mechanisms, involving metabolic and epigenetic reprogramming of innate immune cells 9.
Evidence of Efficacy
Numerous double-blind, placebo-controlled trials demonstrate AIT is efficacious for allergic rhinitis, allergic conjunctivitis, allergic asthma, and stinging insect hypersensitivity 7. Meta-analyses confirm significant reductions in symptoms and medication use 7.
Disease-Altering Benefits
Clinicians should educate patients that AIT can 1:
- Prevent new allergen sensitizations in monosensitized children 6
- Reduce the risk of developing allergic asthma in patients with allergic rhinitis 7, 6
- Alter the natural history of disease with continued benefit after discontinuation 1
These preventive effects distinguish AIT from all other allergy treatments—it's the only therapy that can modify disease trajectory 8, 2.
Treatment Approach
Patient Selection
Before initiating AIT, you must:
- Confirm allergen-specific IgE through testing (skin prick or serum IgE) 2
- Correlate positive tests with clinical history and exposure patterns 1
- Evaluate for asthma or refer for asthma evaluation 1
Absolute Contraindications (Do NOT initiate) 1:
- Pregnancy
- Uncontrolled asthma (critical safety issue)
- Unable to tolerate injectable epinephrine
Relative Contraindications (may choose not to initiate) 1:
- Concomitant beta-blocker use
- History of anaphylaxis
- Systemic immunosuppression
- Eosinophilic esophagitis (for SLIT only)
Treatment Options
Educate patients about SCIT (subcutaneous) versus SLIT (sublingual) options 1:
SCIT (Subcutaneous Immunotherapy):
- Administered in physician's office
- Requires observation period after injection
- Effective maintenance dose: 5-20 mcg of major allergen 7
SLIT (Sublingual Immunotherapy):
- Patient self-administers at home
- Available as tablets (FDA-approved for grass, ragweed, dust mites, birch-homologous trees) or drops (off-label) 8
- For seasonal allergies, offer pre- and co-seasonal therapy 1
Allergen Selection
Limit treatment to only clinically relevant allergens confirmed by both history AND testing 1. You may treat polysensitized patients with a limited number of allergens rather than including every positive test 1.
Treatment Duration
Treat for a minimum of 3 years for patients experiencing symptomatic control, with ongoing duration based on patient response 1. This extended duration is necessary to achieve lasting immune tolerance 1.
Monitoring
Avoid repeat allergy testing during ongoing AIT unless there's a change in environmental exposures or loss of symptom control 1. Testing doesn't assess efficacy—clinical response does.
Common Pitfalls
- Don't withhold AIT due to local reactions—continue escalation or maintenance dosing when patients have local reactions 1
- Don't check asthma control only once—assess for uncontrolled asthma signs before each subsequent dose 1
- Don't use unproven methods like neutralization-provocation therapy or low-dose Rinkel technique, which are ineffective 7
- Don't stop too early—benefits require sustained treatment and may continue to accrue beyond 3 years 1
Environmental Context
Recent research demonstrates that immunostimulatory environmental exposures generate cross-reactive adaptive immune memory that protects against allergic sensitization 3. This mechanistic finding supports why early-life environmental diversity may prevent allergy development and validates AIT's approach of controlled allergen exposure to restore proper immune function.